Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 1, 2016, Pages 26-38

  Gomez Sanchez, Elise P ^a,b  

^a Departments of Pharmacology and Toxicology   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

aldosterone; cardiovascular; cortisol; hyperkalemia; Mineralocorticoid receptor; sympathetic

Indexed keywords

DIHYDROPYRIDINE; MINERALOCORTICOID ANTAGONIST; PYRAZOLINE DERIVATIVE; SULFONAMIDE; MINERALOCORTICOID RECEPTOR; PROTEIN BINDING; SPIRONOLACTONE;

ARTICLE; DRUG DEVELOPMENT; DRUG SELECTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PUBLISHING; ANIMAL; HYPERALDOSTERONISM; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRENDS;

ANIMALS; DRUG DISCOVERY; HUMANS; HYPERALDOSTERONISM; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROTEIN BINDING; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SPIRONOLACTONE;

EID: 84954233101     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000329     Document Type: Article

References (197)

1. Arriza JW, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268-275.
2. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257-263.
3. Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol. 2014;4:965-994.
4. Fuller PJ. Novel interactions of the mineralocorticoid receptor. Mol Cell Endocrinol. 2015;408:33-37.
5. Rogerson FM, Yao YZ, Young MJ, et al. Identification and characterization of a ligand-selective mineralocorticoid receptor coactivator. FASEB J. 2014;28:4200-4210.
6. Fuller PJ, Yao Y, Yang J, et al. Mechanisms of ligand specificity of the mineralocorticoid receptor. J Endocrinol. 2012;213:15-24.
7. Yang J, Chang CY, Safi R, et al. Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display. Mol Endocrinol. 2011;25:32-43.
8. Petit-Topin I, Fay M, Resche-Rigon M, et al. Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors. J Steroid Biochem Mol Biol. 2014;144(pt B):427-435.
9. Arriza JL, Simerly RB, Swanson LW, et al. The neuronal mineralocorticoid receptor as a mediator of glucocorticoid response. Neuron. 1988;1:887-900.
10. Gomez-Sanchez EP. Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis. Steroids. 2014;91:20-31.
11. Kuhlman D, Ragan C, Ferrebee JW, et al. Toxic effects of deoxycorticosterone esters in dogs. Science. 1939;90:496-497.
12. Vinson GP. The mislabelling of deoxycorticosterone: making sense of corticosteroid structure and function. J Endocrinol. 2011;211:3-16.
13. Failla D, Tomkins GM, Santi DV. Partial purification of a glucocorticoid receptor. Proc Natl Acad Sci USA. 1975;72:3849-3852.
14. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53:58-68.
15. Sharma KK, Lindqvist A, Zhou XJ, et al. Deoxycorticosterone inactivation by akr1c3 in human mineralocorticoid target tissues. Mol Cell Endocrinol. 2006;248:79-86.
16. Ahmed AH, Gordon RD, Taylor PJ, et al. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men J Clin Endocrinol Metab. 2011;96:E340-E346.
17. Samuels MH, Brandon DD, Isabelle LM, et al. Cortisol production rates in subjects with suspected cushing's syndrome: assessment by stable isotope dilution methodology and comparison to other diagnostic methods. J Clin Endocrinol Metab. 2000;85:22-28.
18. Reul JM, De Kloet ER. Two receptor systems for coticosterone in rat brain: microdistribution and differential occupation. Endocrinology. 1985;117:2505-2511.
19. Satoh F, Morimoto R, Ono Y, et al. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. Hypertension. 2015;65: 1096-1102.
20. Gomez-Sanchez CE, Rossi GP, Fallo F, et al. Progress in primary aldosteronism: present challenges and perspectives. Horm Metab Res. 2010;42:374-381.
21. Nguyen G, Blanchard A, Curis E, et al. Plasma soluble (pro)renin receptor is independent of plasma renin, prorenin, and aldosterone concentrations but is affected by ethnicity. Hypertension. 2014;63:297-302.
22. Hammond GL, Smith CL, Paterson NA, et al. A role for corticosteroidbinding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab. 1990;71:34-39.
23. Simard M, Hill LA, Underhill CM, et al. Pseudomonas aeruginosa elastase disrupts the cortisol-binding activity of corticosteroid-binding globulin. Endocrinology. 2014;155:2900-2908.
24. Beishuizen A, Thijs LG, Vermes I. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med. 2001;27:1584-1591.
25. Moisan MP, Minni AM, Dominguez G, et al. Role of corticosteroid binding globulin in the fast actions of glucocorticoids on the brain. Steroids. 2014;81:109-115.
26. Mattos GE, Heinzmann JM, Norkowski S, et al. Corticosteroid-binding globulin contributes to the neuroendocrine phenotype of mice selected for extremes in stress reactivity. J Endocrinol. 2013;219:217-229.
27. Deak T, Nguyen KT, Cotter CS, et al. Long-term changes in mineralocorticoid and glucocorticoid receptor occupancy following exposure to an acute stressor. Brain Res. 1999;847:211-220.
28. Gomez-Sanchez EP, Gomez-Sanchez MT, de Rodriguez AF, et al. Immunohistochemical demonstration of the mineralocorticoid receptor, 11{beta}-hydroxysteroid dehydrogenase-1 and-2, and hexose-6-phosphate dehydrogenase in rat ovary. J Histochem Cytochem. 2009; 57:633-641.
29. Odermatt A, Atanasov AG. Mineralocorticoid receptors: emerging complexity and functional diversity. Steroids. 2009;74:163-171.
30. Shekhtman E, Geerling JC, Loewy AD. Aldosterone-sensitive neurons of the nucleus of the solitary tract: multisynaptic pathway to the nucleus accumbens. J Comp Neurol. 2007;501:274-289.
31. Scott JS, Bowker SS, Deschoolmeester J, et al. Discovery of a potent, selective, and orally bioavailable acidic 11beta-hydroxysteroid dehydrogenase type 1 (11beta-hsd1) inhibitor: discovery of 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acet ic acid (azd4017). J Med Chem. 2012;55:5951-5964.
32. Harris AP, Holmes MC, de Kloet ER, et al. Mineralocorticoid and glucocorticoid receptor balance in control of hpa axis and behaviour. Psychoneuroendocrinology. 2013;38:648-658.
33. Bujalska IJ, Walker EA, Hewison M, et al. A switch in dehydrogenase to reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab. 2002;87:1205-1210.
34. Chen J, Gomez-Sanchez CE, Penman A, et al. Expression of mineralocorticoid and glucocorticoid receptors in preautonomic neurons of the rat paraventricular nucleus. Am J Physiol Regul Integr Comp Physiol. 2014;306:R328-R340.
35. de Kloet ER, Karst H, Joels M. Corticosteroid hormones in the central stress response: quick-and-slow. Front Neuroendocrinol. 2008;29: 268-272.
36. Conway-Campbell BL, Sarabdjitsingh RA, McKenna MA, et al. Glucocorticoid ultradian rhythmicity directs cyclical gene pulsing of the clock gene period 1 in rat hippocampus. J Neuroendocrinol. 2010;22: 1093-1100.
37. Sarabdjitsingh RA, Joels M, de Kloet ER. Glucocorticoid pulsatility and rapid corticosteroid actions in the central stress response. Physiol Behav. 2012;106:73-80.
38. Joels M, Sarabdjitsingh RA, Karst H. Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes. Pharmacol Rev. 2012;64:901-938.
39. Youm JK, Park K, Uchida Y, et al. Local blockade of glucocorticoid activation reverses stress-and glucocorticoid-induced delays in cutaneous wound healing. Wound Repair Regen. 2013;21:715-722.
40. Tiganescu A, Tahrani AA, Morgan SA, et al. 11beta-hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J Clin Invest. 2013;123:3051-3060.
41. Fraccarollo D, Galuppo P, Schraut S, et al. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension. 2008;51:905-914.
42. Ward MR, Kanellakis P, Ramsey D, et al. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation. 2001;104:467-472.
43. Gomez-Sanchez EP, Gomez-Sanchez CE. Primary aldosteronism. In: Re RN, DiPette DJ, Schiffrin EL, et al, eds. Molecular Mechanisms in Hypertension'. London, United Kingdom; New York, NY: Taylor & Francis; 2006:113-121.
44. Ueda K, Nagase M. Mineralocorticoid receptor activation as an etiological factor in kidney diseases. Clin Exp Nephrol. 2014;18:16-23.
45. Nagase M, Fujita T. Role of rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nature reviews. Nephrology. 2013;9: 86-98.
46. Mihailidou AS, Loan Le TY, Mardini M, et al. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009;54:1306-1312.
47. Trapp T, Rupprecht R, Castren M, et al. Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the cns. Neuron. 1994;13: 1457-1462.
48. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol. 2001;280:F181-F192.
49. Ackermann D, Gresko N, Carrel M, et al. In vivo nuclear translocation of mineralocorticoid and glucocorticoid receptors in rat kidney: differential effect of corticosteroids along the distal tubule. Am J Physiol Renal Physiol. 2010;299:F1473-F1485.
50. Steiger M, Reichstein T. Desoxy-corticosterone (21-oxy-progesterone). Aus d-3-oxo-etiocholensaüre. Helv Chim Acta. 1937;20:1164.
51. Rodbard S, Freed SC. The effect of desoxycorticosterone acetate on the blood pressure of the dog. Endocrinology. 1942;30:365-368.
52. Relman AJ, Schwartz WB. The effect of doca on electrolyte balance in normal man and its relation to sodium intake. Yale J Biol Med. 1952;24: 540-556.
53. Raab W, Humphreys RJ, Lepeschkin E. Potentiation of pressor effects of nor-epinephrine and epinephrine in man by desoxycorticosterone acetate. J Clin Invest. 1950;29:1397-1404.
54. Vanatta JC, Cottle KE. Effect of desoxycorticosterone acetate on the peripheral vascular reactivity of dogs. Am J Physiol. 1955;151:119-122.
55. Hall CE, Hall O. Interaction between deoxycorticosterone treatment, fluid intake, sodium consumption, blood pressure, and organ changes in rats during drinking water, saline, or sucrose solution. J Physiol Pharmacol. 1969;47:81-86.
56. Simpson SA, Tait JF, Wettstein A, et al. Konstitution des aldosterons, des neuen mineralocorticoids. Experientia. 1953;10:132-133.
57. Conn JW. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3-7.
58. Hood WG Jr, Hill R Jr, Pittman JA Jr, et al. Studies on the metabolic effects of spironolactone in man. Ann N Y Acad Sci. 1960;88:864-880.
59. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol. 2012; 350:310-317.
60. Tanz RD. Studies on the inotropic action of aldosterone on isolated cardiac tissue preparations: including the effect of ph, ouabain and sc-8109. J Pharmacol Exp Ther. 1962;135:71-78.
61. Jones AW, Hart RG. Altered ion transport in aortic smooth muscle during deoxycorticosterone acetate hypertension in rats. Circ Res. 1975;37:333-341.
62. Reid JL, Zivin JA, Kovin IF. Central and peripheral adrenergic mechanisms in the development of deoxycorticosterone-saline hypertension in rats. Circ Res. 1975;37:569-579.
63. Kubo T, Hashimoto M. Effects of intraventricular and intraspinal 6-hyroxydopamine and blood pressure of doca-saline hypertensive rats. Arch Int Pharmacodyn Ther. 1979;238:50-59.
64. Brody MJ, Haywood JR, Touw KB. Neural mechanisms in hypertension. Annu Rev Physiol. 1978;42:441-453.
65. Berecek KH, Murray RD, Gross F. Significance of sodium, sympathetic innervation and central adrenergic structures on renal vascular responsiveness in doca-treated rats. Circ Res. 1980;47:675-683.
66. Guyton AC. Dominant role of the kidneys and accessory role of wholebody autoregulation in the pathogenesis of hypertension. Am J Hypertens. 1989;2:575-585.
67. Cascella T, Palomba S, Tauchmanova L, et al. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2006;91:4395-4400.
68. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514-523.
69. Kelestimur F. Diane 35 and spironolactone combination in the treatment of hirsutism. Clin Endocrinol (Oxf). 2001;54:699-700.
70. Oelkers WK. Effects of estrogens and progestogens on the reninaldosterone system and blood pressure. Steroids. 1996;61:166-171.
71. Boschitsch E,Mayerhofer S,Magometschnigg D. Hypertension in women: the role of progesterone and aldosterone. Climacteric. 2010;13:307-313.
72. Caprio M, Antelmi A, Chetrite G, et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011; 152:113-125.
73. Nisenbaum MG, de Melo NR, Giribela CR, et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol. 2014;175:62-66.
74. Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013;347:f5298.
75. Luther JM. Is there a new dawn for selective mineralocorticoid receptor antagonism Curr Opin Nephrol Hypertens. 2014;23:456-461.
76. Torreli V, Hardy M, Nedelec L, et al. 7-alkyl spironolactones as potent aldosterone antagonists. J Steroid Biochem. 1982;17(suppl III):17.
77. Gomez-Sanchez EP, Fort CM, Gomez-Sanchez CE. Intracerebroventricular infusions of ru28318 blocks aldosterone-salt hypertension. Am J Physiol. 1990;258:E482-E484.
78. van den Berg DT, De Kloet ER, van Dijken HH, et al. Differential central effects of mineralocorticoid and glucocorticoid agonists and antagonists on blood pressure. Endocrinology. 1990;126:118-124.
79. Gomez-Sanchez EP, Fort C, Thwaites D. Central mineralocorticoid receptor antagonism blocks hypertension in dahl S/JR rats. Am J Physiol. 1992;262:E96-E99.
80. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxyspirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650-656.
81. de Gasparo M, Whitebread SE, Preiswerk G, et al. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem. 1989;32:223-227.
82. Borghi C, Boschi S, Ambrosioni E, et al. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ace inhibitors. J Clin Pharmacol. 1993;33: 40-45.
83. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995;9:145-149.
84. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29:13-21.
85. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-575.
86. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:12A-16A.
87. Brilla CG, Zhou G, Matsubara L, et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin ii and aldosterone. J Mol Cell Cardiol. 1994;26:809-820.
88. Young MJ, Funder JW. Mineralocorticoids, salt, hypertension: effects on the heart. Steroids. 1996;61:233-235.
89. Gomez-Sanchez EP, Zhou MY, Gomez-Sanchez CE. Mineralocorticoids, salt and high blood pressure: causes. Steroids. 1996;61:184-188.
90. Rocha R, Chander PN, Khanna K, et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31:451-458.
91. Pitt B, Zannad F, Cody R, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341: 709-717.
92. Danjuma MI, Mukherjee I, Makaronidis J, et al. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep. 2014;16:414.
93. Pfeffer MA. New treasures from old Ephesus. Eplerenome post-ahi heart failure efficacy and survival study. Cardiovasc Drugs Ther. 2001;15:11-13.
94. Mavrakanas TA, Gariani K, Martin PY. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin ii receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Eur J Intern Med. 2014; 25:173-176.
95. Hargovan M, Ferro A. Aldosterone synthase inhibitors in hypertension: current status and future possibilities. JRSM Cardiovasc Dis. 2014;3: 2048004014522440.
96. Tamargo J, Solini A, Ruilope LM. Comparison of agents that affect aldosterone action. Semin Nephrol. 2014;34:285-306.
97. Mokler CM. Antiarrhythmic activity of various steroidal spirolactones in dogs. Proc Soc Exp Biol Med. 1960;105:257-259.
98. Simopoulos V, Tagarakis G, Hatziefthimiou A, et al. Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study. Clin Res Cardiol. 2015;104:31-37.
99. Liu X, Yu H, Pei J, et al. Clinical characteristics and long-term prognosis in patients with chronic heart failure and reduced ejection fraction in china. Heart Lung Circ. 2014;23:818-826.
100. Beygui F, Vicaut E, Ecollan P, et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the albatross trial. Am Heart J. 2010;160:642-648.
101. Le Menuet D, Munier M, Meduri G, et al. Mineralocorticoid receptor overexpression in embryonic stem cell-derived cardiomyocytes increases their beating frequency. Cardiovasc Res. 2010;87:467-475.
102. Le Menuet D, Viengchareun S, Muffat-Joly M, et al. Expression and function of the human mineralocorticoid receptor: lessons from transgenic mouse models. Mol Cell Endocrinol. 2004;217:127-136.
103. Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85: 1207-1211.
104. Xue B, Beltz TG, Yu Y, et al. Central interactions of aldosterone and angiotensin ii in aldosterone-and angiotensin ii-induced hypertension. Am J Physiol Heart Circ Physiol. 2011;300:H555-H564.
105. Schmiedek P, Sadee W, Baethmann A. Cerebral uptake of a 3 h-labelled spirolactone compound in the dog. Eur J Pharmacol. 1973;21:238-241.
106. Kang YM, Zhang ZH, Johnson RF, et al. Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. Circ Res. 2006;99:758-766.
107. Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94:1361-1366.
108. Raheja P, Price A, Wang Z, et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension. 2012;60:319-325.
109. Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol. 2005;19:2211-2221.
110. Tirard M, Almeida OF, Hutzler P, et al. Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor. Mol Cell Endocrinol. 2007;268:20-29.
111. Yokota K, Shibata H, Kurihara I, et al. Coactivation of the n-terminal transactivation of mineralocorticoid receptor by ubc9. J Biol Chem. 2007;282:1998-2010.
112. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome p450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116: 496-526.
113. Thomas M, Burk O, Klumpp B, et al. Direct transcriptional regulation of human hepatic cytochrome p450 3a4 (cyp3a4) by peroxisome proliferator-activated receptor alpha (pparalpha). Mol Pharmacol. 2013;83:709-718.
114. Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-716.
115. Parthasarathy HK, Menard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29:980-990.
116. Miller RJ, Howlett JG. Evolving role for mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction. Curr Opin Cardiol. 2015;30:168-172.
117. Azizi M, Perdrix L, Bobrie G, et al. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. J Hypertens. 2014;32:2038-2044.
118. Funder JW. Mineralocorticoid-receptor blockade, hypertension and heart failure. Nat Clin Pract Endocrinol Metab. 2005;1:4-5.
119. Funder JW. Rales, ephesus and redox. J Steroid Biochem Mol Biol. 2005;93:121-125.
120. Collin M, Niemann F, Jaisser F. Mineralocorticoid receptor modulators: a patent review (2007-2012). Expert Opin Ther Pat. 2014;24:177-183.
121. Vukusich A, Kunstmann S, Varela C, et al. A randomized, doubleblind, placebo-controlled trial of spironolactone on carotid intimamedia thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:1380-1387.
122. Epstein M. Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease. Lancet Diabetes Endocrinol. 2014;2:925-927.
123. Perez-Gomez MV, Sanchez-Nino MD, Sanz AB, et al. Horizon 2020 in diabetic kidney disease: the clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade. J Clin Med. 2015;4:1325-1347.
124. Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study [published online ahead of print May 26, 2015]. Retina. 2015. doi:10.1097/IAE.0000000000000614.
125. Zhao M, Celerier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122:2672-2679.
126. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009;53:286-290.
127. Gomez-Sanchez CE. Primary aldosteronism: a channelopathy Hypertension. 2014;63:668-669.
128. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist bay 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453-2463.
129. Orena S, Maurer TS, She L, et al. Pf-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol. 2013;4:115.
130. Casimiro-Garcia A, Piotrowski DW, Ambler C, et al. Identification of (r)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1hpyrazol-3-yl)-2-me thoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist. J Med Chem. 2014;57:4273-4288.
131. Nariai T, Fujita K, Mori M, et al. Sm-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats. J Cardiovasc Pharmacol. 2012;59:458-464.
132. Futatsugi K, Piotrowski DW, Casimiro-Garcia A, et al. Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists. Bioorg Med Chem Lett. 2013;23:6239-6242.
133. Nariai T, Fujita K, Kawane K, et al. Dsr-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats. J Pharmacol Exp Ther. 2015;354:2-9.
134. Schiebinger RJ, Braley LM, Menachery A, et al. Unique calcium dependencies of the activating mechanism of the early and late aldosterone biosynthetic pathways in the rat. J Endocrinol. 1986;110:315-325.
135. Barrett PQ, Ertel EA, Smith MM, et al. Voltage-gated calcium currents have two opposing effects on the secretion of aldosterone. Am J Physiol. 1995;268:C985-C992.
136. Rossier MF, Burnay MM, Maturana A, et al. Duality of the voltagedependent calcium influx in adrenal glomerulosa cells. Endocr Res. 1998;24:443-447.
137. Dietz JD, Du S, Bolten CW, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008;51:742-748.
138. Arhancet GB, Woodard SS, Dietz JD, et al. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J Med Chem. 2010;53:4300-4304.
139. Kosaka H, Hirayama K, Yoda N, et al. The l-, n-, and t-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol. 2010;635:49-55.
140. Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285:29932-29940.
141. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119-123.
142. Arhancet GB, Woodard SS, Iyanar K, et al. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists. J Med Chem. 2010;53:5970-5978.
143. Lavall D, Selzer C, Schuster P, et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem. 2014; 289:6656-6668.
144. Barfacker L, Kuhl A, Hillisch A, et al. Discovery of bay 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385-1403.
145. Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69-78.
146. Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015; 24:417-424.
147. Pitt B, Anker SD, Bohm M, et al. Rationale and design of mineralocorticoid receptor antagonist tolerability study-heart failure (arts-hf): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17:224-232.
148. Ruilope LM, Agarwal R, Chan JC, et al. Rationale, design, and baseline characteristics of arts-dn: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014;40: 572-581.
149. Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of arts: a randomized, double-blind study of bay 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012;14:668-675.
150. Kontak AC, Wang Z, Arbique D, et al. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab. 2010;95:4756-4761.
151. Bakris GL, Agarwal R, Chan JC, et al, Mineralocorticoid receptor antagonist tolerability study-diabetic nephropathy study G. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884-894.
152. Meyers MJ, Arhancet GB, Hockerman SL, et al. Discovery of (3s,3ar)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2h-benzo[g] indazole-7-carboxylic acid (pf-3882845), an orally efficacious mineralocorticoid receptor (mr) antagonist for hypertension and nephropathy. J Med Chem. 2010;53:5979-6002.
153. Nariai T, Fujita K, Mori M, et al. Sm-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary na+ excretion activity. J Pharmacol Sci. 2011;115:346-353.
154. Nariai T, Fujita K, Mori M, et al. Antihypertensive and cardiorenal protective effects of sm-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats. Pharmacology. 2012;89:44-52.
155. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, et al. Therapeutic approaches to diabetic nephropathy-beyond the ras. Nat Rev Nephrol. 2014;10:325-346.
156. Cox JM, Chu HD, Yang C, et al. Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series. Bioorg Med Chem Lett. 2014;24:1681-1684.
157. Yang C, Balsells J, Chu HD, et al. Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists. ACS Med Chem Lett. 2015;6:461-465.
158. Yang C, Shen HC, Wu Z, et al. Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists. Bioorg Med Chem Lett. 2013;23:4388-4392.
159. Karst H, Berger S, Turiault M, et al. Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc Natl Acad Sci USA. 2005;102: 19204-19207.
160. Hamstra DA, de Kloet ER, van Hemert AM, et al. Mineralocorticoid receptor haplotype, oral contraceptives and emotional information processing. Neuroscience. 2015;286:412-422.
161. Kruk MR, Haller J, Meelis W, et al. Mineralocorticoid receptor blockade during a rat's first violent encounter inhibits its subsequent propensity for violence. Behav Neurosci. 2013;127:505-514.
162. Gass P, Kretz O, Wolfer DP, et al. Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice. EMBO Rep. 2000;1:447-451.
163. Le Menuet D, Lombes M. The neuronal mineralocorticoid receptor: from cell survival to neurogenesis. Steroids. 2014;91:11-19.
164. Qi XR, Kamphuis W, Wang S, et al. Aberrant stress hormone receptor balance in the human prefrontal cortex and hypothalamic paraventricular nucleus of depressed patients. Psychoneuroendocrinology. 2012;38: 863-870.
165. Xing GQ, Russell S, Webster MJ, et al. Decreased expression of mineralocorticoid receptor mrna in the prefrontal cortex in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol. 2004;7:143-153.
166. De Kloet ER. Hormones and the stressed brain. Ann N Y Acad Sci. 2004;1018:1-15.
167. Cornelisse S, Joels M, Smeets T. A randomized trial on mineralocorticoid receptor blockade in men: effects on stress responses, selective attention, and memory. Neuropsychopharmacology. 2011;36:2720-2728.
168. Otte C, Moritz S, Yassouridis A, et al. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. Neuropsychopharmacology. 2007; 32:232-238.
169. Yau JL, Noble J, Seckl JR. Continuous blockade of brain mineralocorticoid receptors impairs spatial learning in rats. Neurosci Lett. 1999;277:45-48.
170. Wintermantel TM, Berger S, Greiner EF, et al. Evaluation of steroid receptor function by gene targeting in mice. J Steroid Biochem Mol Biol. 2005;93:107-112.
171. Berger S, Bleich M, Schmid W, et al. Mineralocorticoid receptor knockout mice: lessons on na+ metabolism. Kidney Int. 2000;57:1295-1298.
172. Stranahan AM, Arumugam TV, Lee K, et al. Mineralocorticoid receptor activation restores medial perforant path ltp in diabetic rats. Synapse. 2010;64:528-532.
173. Otte C, Hinkelmann K, Moritz S, et al. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res. 2010;44:339-346.
174. Kunzel HE, Apostolopoulou K, Pallauf A, et al. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. J Psychiatr Res. 2012;46:1650-1654.
175. Kunzel HE. Psychopathological symptoms in patients with primary hyperaldosteronism-possible pathways. Horm Metab Res. 2012;44: 202-207.
176. Popa-Wagner A, Buga AM, Popescu B, et al. Vascular cognitive impairment, dementia, aging and energy demand. A vicious cycle. J Neural Transm. 2015;122 Suppl 1:S47-54.
177. Pabbidi MR, Mazur O, Fan F, et al. Enhanced large conductance k+ channel activity contributes to the impaired myogenic response in the cerebral vasculature of fawn hooded hypertensive rats. Am J Physiol Heart Circ Physiol. 2014;306:H989-H1000.
178. Fan F, Geurts AM, Murphy SR, et al. Impaired myogenic response and autoregulation of cerebral blood flow is rescued in cyp4a1 transgenic dahl salt-sensitive rat. Am J Physiol Regul Integr Comp Physiol. 2015; 308:R379-R390.
179. Le Billan F, Khan JA, Lamribet K, et al. Cistrome of the aldosteroneactivated mineralocorticoid receptor in human renal cells. FASEB J. 2015;29:3977-3989.
180. Viengchareun S, Le Menuet D, Martinerie L, et al. The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology. Nucl Recept Signal. 2007;5:e012.
181. Kitada K, Nakano D, Liu Y, et al. Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in dahl salt-sensitive rats. PLoS One. 2012;7:e41896.
182. Bienvenu LA, Morgan J, Rickard AJ, et al. Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology. 2012;153:3416-3425.
183. Zhu X, Manning RD Jr, Lu D, et al. Aldosterone stimulates superoxide production in macula densa cells. Am J Physiol Renal Physiol. 2011; 301:F529-F535.
184. Queisser N, Oteiza PI, Link S, et al. Aldosterone activates transcription factor nrf2 in kidney cells both in vitro and in vivo. Antioxid Redox Signal. 2014;21:2126-2142.
185. Ou XM, Storring JM, Kushwaha N, et al. Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-ht1a receptor gene. J Biol Chem. 2001;276: 14299-14307.
186. Savory JG, Prefontaine GG, Lamprecht C, et al. Glucocorticoid receptor homodimers and glucocorticoid-mineralocorticoid receptor heterodimers form in the cytoplasm through alternative dimerization interfaces. Mol Cell Biol. 2001;21:781-79
187. Yin L, Hu Q, Emmerich J, et al. Novel pyridyl-or isoquinolinylsubstituted indolines and indoles as potent and selective aldosterone synthase inhibitors. J Med Chem. 2014;57:5179-5189.
188. Namsolleck P, Unger T. Aldosterone synthase inhibitors in cardiovascular and renal diseases. Nephrol Dial Transplant. 2014;29(suppl 1): i62-i68.
189. Hu Q, Yin L, Hartmann RW. Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases. J Med Chem. 2014;57:5011-5022.
190. Gros R, Ding Q, Sklar LA, et al. Gpr30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension. 2011;57:442-451.
191. Gros R, Ding Q, Davis M, et al. Delineating the receptor mechanisms underlying the rapid vascular contractile effects of aldosterone and estradiol. Can J Physiol Pharmacol. 2011;89:655-663.
192. Barton M. Position paper: the membrane estrogen receptor gper-clues and questions. Steroids. 2012;77:935-942.
193. Meinel S, Gekle M, Grossmann C. Mineralocorticoid receptor signaling: crosstalk with membrane receptors and other modulators. Steroids. 2014;91:3-10.
194. Wendler A, Albrecht C, Wehling M. Nongenomic actions of aldosterone and progesterone revisited. Steroids. 2012;77:1002-1006.
195. Feldman RD, Gros R. Unraveling the mechanisms underlying the rapid vascular effects of steroids: sorting out the receptors and the pathways. Br J Pharmacol. 2011;163:1163-1169.
196. Zhao Z, Wang H, Jessup JA, et al. Role of estrogen in diastolic dysfunction. Am J Physiol Heart Circ Physiol. 2014;306:H628-H640.
197. Ren Y, D'Ambrosio MA, Garvin JL, et al. Aldosterone sensitizes connecting tubule glomerular feedback via the aldosterone receptor gpr30. Am J Physiol Renal Physiol. 2014;307:F427-F434.